CVS Health (CVS) — Q3 2026 Earnings Preview
Key Points: What to Watch This Quarter
| Factor | Details & Signals to Watch |
|---|---|
| Guidance Revisions | Management has raised FY26 guidance twice YTD; look for further upward revisions or confirmation. |
| Health Care Benefits (HCB) | Margin recovery and MBR improvement are central; watch for continued AOI growth and trend discipline. |
| Pharmacy & Consumer Wellness (PCW) | Mid-single-digit AOI growth expected; sustainability of script share gains and CostVantage margin stability are key. |
| Health Services (HSS) | 340B headwinds and Caremark membership declines flagged for 2027; any intra-quarter updates on these? |
| GLP-1 Category | Direct-to-consumer and funded channel performance, impact on script growth, and margin per script. |
| AI/Tech Investment ROI | Management continues to highlight $20B+ tech investment over 10 years; look for commentary on realized savings and productivity. |
| Cash Flow & Capital Return | YTD cash flow from operations is strong; watch for leverage ratio progress and any update on share repurchase timing. |
Forward Consensus vs. Guidance
FY2026 Guidance and Consensus
| Metric | Latest Company Guidance (Q2 2026) | Prior Guidance (Q1 2026) | Current Consensus* | Notes |
|---|---|---|---|---|
| Revenue ($M) | ≥ $414,000 | ≥ $405,000 | $418,050 | Guidance raised in Q2 |
| Adjusted EPS | $7.90–$8.10 | $7.30–$7.50 | $7.91 | Guidance raised in Q2 |
| GAAP EPS | $6.84–$7.04 | $6.24–$6.44 | $6.87 | Guidance raised in Q2 |
| Cash Flow from Ops ($M) | ≥ $11,500 | ≥ $9,500 | $7,389/share | Guidance raised in Q2 |
| HCB AOI ($M) | $5,030–$5,370 | $4,000–$4,340 | Guidance raised in Q2 | |
| PCW AOI ($M) | ≥ $6,400 | ≥ $6,180 | Guidance raised in Q2 | |
| HSS AOI ($M) | Not updated in Q2 | Confirmed prior guide |
*Consensus figures rounded to millions, as of latest available.
Recent Actuals — Quarterly Trend
Quarterly Financials (Reported)
| Quarter | Revenue ($M) | Adj. EPS | GAAP EPS | Adj. Op Income ($M) | Cash Flow from Ops ($M) |
|---|---|---|---|---|---|
| Q2 2026 | 106,096 | 2.58 | 2.31 | 5,157 | 10,594 (YTD) |
| Q1 2026 | 100,426 | 2.57 | 2.30 | 5,150 | 4,249 |
| Q4 2025 | 105,693 | 1.09 | 2.30 | 2,597 | 10,639 (FY) |
| Q3 2025 | 102,871 | 1.60 | -3.13 | 3,459 | 7,249 (YTD) |
Segment AOI (Adjusted Operating Income, $M)
| Quarter | HCB | HSS | PCW |
|---|---|---|---|
| Q2 2026 | 2,426 | 1,733 | 1,475 |
| Q1 2026 | 3,041 | 1,489 | 1,197 |
| Q4 2025 | -676 | 1,923 | 1,911 |
| Q3 2025 | 314 | 2,050 | 1,478 |
Year-over-Year Comparison: Q3 2025 vs. Q3 2026 Setup
- Q3 2025 Revenue: $102,871M (+7.8% YoY at the time)
- Q3 2025 Adj. EPS: $1.60 (+47% YoY at the time)
- Q3 2025 HCB AOI: $314M (recovery from prior year loss)
- Q3 2025 PCW AOI: $1,478M (-7.4% YoY)
- Q3 2025 HSS AOI: $2,050M (-7.0% YoY)
Q3 2026 consensus revenue is $104,814M (+1.9% YoY vs. Q3 2025 actual), with consensus GAAP EPS of $1.29 (note: consensus is not adjusted EPS).
Takeaway: The company is coming off a period of strong y/y growth in Q3 2025, especially in HCB, but with some segment-level volatility (notably PCW and HSS AOI were down YoY in Q3 2025). The Q3 2026 setup is for a more normalized comp, with consensus expecting modest top-line growth and a much higher run-rate for adjusted EPS and AOI.
Segment Trends and Key Questions
Health Care Benefits (HCB)
- Margin Recovery: HCB AOI guidance for FY26 was raised by >$1B in Q2, reflecting strong Medicare Advantage (MA) performance and disciplined pricing.
- MBR: Q2 2026 MBR was 87.4% (improved 250 bps YoY); full-year MBR guided to 89.75% ±25 bps.
- Commercial/Medicaid: Both performing in line; Medicaid rate advocacy cited as effective.
- Key Q3 Watch: Will MA margin improvement persist? Any sign of trend deterioration or reserve build?
Pharmacy & Consumer Wellness (PCW)
- AOI Growth: Q2 2026 AOI up 10.2% YoY; full-year AOI guidance raised to ≥$6.4B.
- Script Growth: Script volume up 4.3% YoY in Q2; Rite Aid file buys still a tailwind but expected to normalize.
- CostVantage: Management claims margin per script is now stable and fair; watch for commentary on sustainability as share gains normalize.
- Key Q3 Watch: Is mid-single-digit AOI growth sustainable as Rite Aid tailwind fades? Any margin pressure from reimbursement or mix?
Health Services (HSS)
- 340B Headwind: Management called out 340B program as a headwind for 2027, with some impact already in Q2 2026.
- Caremark Membership: Lower retention flagged for 2027 due to disciplined contract renewals and health plan customer exits.
- Specialty Pharmacy: Remains a tailwind; management claims >90% adherence rates and robust generic pipeline.
- Key Q3 Watch: Any incremental 340B or membership headwind? Is specialty offsetting PBM pressures?
GLP-1 and Direct-to-Consumer Initiatives
- GLP-1 Volume: CVS is leveraging both funded (Caremark/Aetna) and cash-pay channels (MinuteClinic, retail pharmacy) for GLP-1s.
- DTC Platform: MinuteClinic virtual visits for weight management now $29; new partnerships with Eli Lilly and Novo for cash pay.
- Margin Impact: CostVantage ensures fair margin per script; management claims 200 bps share gain in GLP-1 category.
- Key Q3 Watch: Is GLP-1 volume growth translating into durable margin and script share? Any regulatory or payer pushback?
Technology and AI Investment
- $20B+ Commitment: Management reiterates $20B+ tech investment over 10 years.
- Productivity: Over $1B in OpEx savings cited; AI deployed in claims, call centers, pharmacy ops.
- Growth vs. Cost: Management emphasizes both cost takeout and growth enablement.
- Key Q3 Watch: Any quantified update on realized savings or new AI-driven revenue/cost initiatives?
Capital Allocation
- Leverage: Q2 2026 leverage ratio ~3.5x, improved from 5x in 2024.
- Share Repurchase: No buybacks assumed in 2026/2027 guidance; management signals potential for resumption as leverage improves.
- Dividend: Ongoing commitment to dividend.
- Key Q3 Watch: Any update on timing for share repo or bolt-on M&A?
Summary and Conclusions
- Momentum Across Segments: CVS enters Q3 2026 with strong momentum in HCB (margin recovery), PCW (mid-single-digit AOI growth), and HSS (specialty tailwinds, but 340B/retention headwinds for 2027).
- Guidance Trajectory: Management has consistently raised FY26 guidance; consensus is now aligned with the upper end of the range.
- Comparables: Q3 2025 was a strong quarter, especially for HCB; Q3 2026 faces a tougher comp but is set up for continued growth.
- Risks: 340B headwinds, PBM contract churn, normalization of script share gains, and macro medical cost trends.
- Catalysts: Q3 print, Q4 guidance update, clarity on 2027 headwinds/tailwinds, and any capital return announcements.
Bottom Line: The most important factors for Q3 2026 are confirmation of continued margin recovery in HCB, sustainability of PCW AOI growth as share gains normalize, quantification of 340B and Caremark membership headwinds for 2027, and any incremental upward revision to FY26 guidance. Watch for updates on technology ROI and capital deployment as leverage improves.
